Bioeffective® R

Bioeffective® R  is currently sold in Russia as Ropren® Drops (Ropren), a registered prescription pharmaceutical hepatoprotector used in the treatment of liver disease.
Bioeffective® R is a biologically active product extracted using sophisticated patented technology from neutral extractive substances of the green needles of several conifer species, in particular European fir (Picea abies (L) Karst), and Scotch pine (Pinus sylvestris).

Bioeffective® R consists of a mixture of polyprenols (acyclic isoprenoid alcohols) homologues containing primarily 13 - 18 isoprene units, of very high purity.

It also contains carotenoids and vitamin E, and is obtained as a clear, pale orange-yellow, oily liquid, with a slight coniferous odour.
These polyprenols are naturally occurring analogues and precursors of dolichol, and play an important role in all vital functions and are essential in cellular biosynthesis of glycopeptides (glycoproteins).
Bioeffective® R has been shown to be virtually non-toxic (LD50> 10,000 mg/kg), non-irritant, non-mutagenic, and non-carcinogenic.

In 2007, Ropren (Bioeffective ® R) was approved by the Russian Ministry of Health for entry into the Russian Pharmacopoeia as a hepatoprotector for use in treating chronic hepatitis and hepatobiliary dysfunction -  with monographs for both the active raw material (“Ropren® substance”) and the finished product (“Ropren® drops”), a solution of Bioeffective® R in a pharmaceutical grade oil.

As such, it is the only natural medication of Russian origin to be registered in Russia for over 20 years.

Ropren has been the subject of extensive clinical trials to confirm its efficacy and safety in the treatment of liver disease.

The trials in Russia also showed that Ropren had significantly wider applications than liver disease. This included the ability to normalise immune response and normalise cholesterol levels, as well as alleviate the symptoms of neurodegenerative disorders including Alzheimer’s disease and Parkinson's disease, alcoholism, drug addiction and depression.  A trial conducted at the Brain Sciences Institute at Swinburne University in Melbourne, Australia, in 2006, confirmed certain neurocognitive effects of Ropren identified previously in Russia.

A Russian manufacturing license was awarded in February 2008 for the manufacture of Ropren through a GMP certified contract manufacturer. In January 2010, the company received from the Russian Health Control Authority a Pharmaceutical Wholesale Distribution License.

Commercial sales of Ropren in Russia for the treatment of a number of liver diseases commenced in February 2010